Rusnati Marco

Responsabile dell'U.O.

Cognome e Nome

Rusnati Marco

Qualifica

PO

Dipartimento

Molecular and Translational Medicine, University of Brescia

Settore scientifico disciplinare

MED04 “Patologia Generale”

E-mail

marco.rusnati@unibs.it

Telefono

+39-030-3717315 cell: +39-366-6692550

Personale strutturato

Cognome e Nome

Urbinati Chiara

Qualifica

Technician

Dipartimento

Molecular and Translational Medicine

Ente di appartenenza

University of Brescia

Cognome e Nome

Grillo Elisabetta

Qualifica

RTDB

Dipartimento

Molecular and Translational Medicine

Ente di appartenenza

University of Brescia

Cognome e Nome

Tobia Chiara

Qualifica

Technician

Dipartimento

Molecular and Translational Medicine

Ente di appartenenza

University of Brescia

Personale non strutturato

Cognome e Nome

Milanesi Maria

Qualifica

Ph.D student

Dipartimento

Molecular and Translational Medicine

Ente di appartenenza

University of Brescia

Cognome e Nome

Rondina Alessandro

Qualifica

Ph.D student

Dipartimento

Molecular and Translational Medicine

Ente di appartenenza

University of Brescia

Linee di ricerca

1983-1985: Purification and biochemical characterization of D-amino acid oxidase. 1986-1992: Purification and characterization angiogenic factors (FGFs), identification of their functional domains. 1992-present: Interaction of FGFs with their receptors and co-receptors present onto the cell-membrane or in the extracellular matrix of endothelium. 1996-present: Extracellular activity of HIV Tat, gp120 and p17, study of their interaction with soluble, extracellular matrix or cell-associated binders/receptors. 2001-present: Study of molecular interaction by surface plasmon resonance (BIAcore technology). 2006-present: Study of the role of glycosilation of integrins and VEGFR2 in angiogenesis 2008-present: Development of inhibitor of HPV, HSV & RSV infection. 2015-present: Screening of compounds acting as antagonists of the Eph-ephrin system; screening of compounds acting as cystic fibrosis therapeutics.

Tecnologie in uso dall'UO

  1. 1.
    Recombinant proteins
  2. 2.
    Angiogenesis assays
  3. 3.
    Fast liquid protein chromatography
  4. 4.
    Surface plasmon resonance interaction assay
  5. 5.
    Time-lapse microscopy
  6. 6.
    Protein mutagenesis
  7. 7.
    Retro and lentivirus cell transfection
  8. 8.
    Microscale thermophoresis

Strumentazione

Denominazione

BIACORE X-100 surface plasmon resonance unit for macromolecular interaction assay
MST MONOLITH NT.115 for microscale thermophoresis interaction assay

Struttura ove la strumentazione è allocata

Section of Experimental Oncology and Immunology
Section of Experimental Oncology and Immunology

Responsabile

Prof. Marco Rusnati
Prof. Marco Rusnati

Pubblicazioni

  1. 1.
    Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays A Parodi, G Righetti, E Pesce, A Salis, B Tasso, C Urbinati, V Tomati, ... European Journal of Medicinal Chemistry 208, 112833, 2020
  2. 2.
    In silico drug repositioning on F508del-CFTR: A proof-of-concept study on the AIFA library A Orro, M Uggeri, M Rusnati, C Urbinati, N Pedemonte, E Pesce, ... European Journal of Medicinal Chemistry 213, 113186, 2021
  3. 3.
    The FGF/FGFR system in the physiopathology of the prostate gland 3 A Giacomini, E Grillo, S Rezzola, D Ribatti, M Rusnati, R Ronca, M Presta Physiological Reviews 101 (2), 569-610, 2021
  4. 4.
    A Bittersweet Computational Journey among Glycosaminoglycans G Paiardi, M Milanesi, RC Wade, P D’Ursi, M Rusnati Biomolecules 11 (5), 739, 2021
  5. 5.
    HIV-1 Tat and Heparan Sulfate Proteoglycans Orchestrate the Setup of in Cis and in Trans Cell-Surface Interactions Functional to Lymphocyte Trans-Endothelial … C Urbinati, M Milanesi, N Lauro, C Bertelli, G David, P D’Ursi, M Rusnati, ... Molecules 26 (24), 7488, 2021
  6. 6.
    Metabolic soft spot and pharmacokinetics: Functionalization of C-3 position of an Eph–ephrin antagonist featuring a bile acid core as an effective strategy to obtain oral … F Ferlenghi, C Giorgio, M Incerti, L Guidetti, P Chiodelli, M Rusnati, ... Pharmaceuticals 15 (1), 4, 2021
  7. 7.
    The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms G Paiardi, S Richter, P Oreste, C Urbinati, M Rusnati, RC Wade Journal of Biological Chemistry 298 (2), 2022
  8. 8.
    Prevention of Herpesviridae Infections by Cationic PEGylated Carbosilane Dendrimers E Royo-Rubio, V Martín-Cañadilla, M Rusnati, M Milanesi, T Lozano-Cruz, ... Pharmaceutics 14 (3), 536, 2022
  9. 9.
    Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin M Rusnati, G Paiardi, C Tobia, C Urbinati, A Lodola, P D’Ursi, M Corrado, ... Cancer Gene Therapy 29 (7), 1070-1070, 2022
  10. 10.
    Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing P Fossa, M Uggeri, A Orro, C Urbinati, A Rondina, M Milanesi, ... International Journal of Molecular Sciences 23 (20), 12274, 2022

Dottorati di ricerca

Componente UO

Rusnati Marco

Dottorato di ricerca

Technology for Health

Coordinatore

Prof. Nicola lopomo

Sede

Brescia